þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
26-2593535
|
|
(State of incorporation)
|
(I.R.S. Employer Identification No.)
|
Large accelerated filer
o
|
Accelerated filer
þ
|
Non-accelerated filer
o
|
Smaller reporting company
o
|
(Do not check if a smaller reporting company)
|
PAGE
|
||
PART I. FINANCIAL INFORMATION
|
||
2
|
||
2
|
||
3
|
||
4
|
||
6
|
||
16
|
||
22
|
||
23
|
||
PART II. OTHER INFORMATION
|
||
24
|
||
24
|
||
24
|
||
24
|
||
24
|
||
24
|
||
24
|
July 31,
2015
|
April 30,
2015
|
|||||||
(Unaudited)
|
||||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$ | 3,650,855 | $ | 7,926,491 | ||||
Marketable securities
|
17,661,213 | 9,200,082 | ||||||
Accounts receivable
|
98,594 | 76,475 | ||||||
Prepaid expenses
|
162,689 | 249,505 | ||||||
Other current assets
|
29,144 | 58,623 | ||||||
Total current assets
|
21,602,495 | 17,511,176 | ||||||
Marketable securities
|
22,561,050 | 30,974,961 | ||||||
Property and equipment, net
|
54,361 | 50,322 | ||||||
Intangible assets, net
|
22,000,000 | 22,000,000 | ||||||
Goodwill
|
11,265,100 | 11,265,100 | ||||||
Other assets
|
1,106,785 | 1,106,785 | ||||||
Total assets
|
$ | 78,589,791 | $ | 82,908,344 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities
|
||||||||
Accounts payable
|
$ | 680,692 | $ | 1,183,939 | ||||
Accrued liabilities
|
1,919,580 | 2,660,666 | ||||||
Warrant liabilities
|
606,118 | 572,445 | ||||||
Notes payable, net
|
48,376 | 100,160 | ||||||
Total current liabilities
|
3,254,766 | 4,517,210 | ||||||
Deferred tax liability
|
7,962,100 | 7,962,100 | ||||||
Total liabilities
|
11,216,866 | 12,479,310 | ||||||
Commitments and contingencies; see Note 6
|
||||||||
Stockholders' equity
|
||||||||
Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 28,119,607 and 28,119,520, respectively
|
2,812 | 2,812 | ||||||
Additional paid-in capital
|
221,111,504 | 221,067,239 | ||||||
Accumulated other comprehensive (loss)/gain
|
(39,156 | ) | 26,718 | |||||
Accumulated deficit
|
(153,702,235 | ) | (150,667,735 | ) | ||||
Total stockholders’ equity
|
67,372,925 | 70,429,034 | ||||||
Total liabilities and stockholders' equity
|
$ | 78,589,791 | $ | 82,908,344 |
Three months ended July 31,
|
||||||||
2015
|
2014
|
|||||||
(Unaudited)
|
(Unaudited)
|
|||||||
Operating expenses
|
||||||||
General and administrative
|
$ | 1,368,604 | $ | 1,449,859 | ||||
Research and development
|
1,745,901 | 966,514 | ||||||
Total operating expenses
|
3,114,505 | 2,416,373 | ||||||
Net operating loss
|
3,114,505 | 2,416,373 | ||||||
Interest expense
|
1,103 | 46,260 | ||||||
Other income
|
(81,108 | ) | (291,221 | ) | ||||
Net loss
|
$ | 3,034,500 | $ | 2,171,412 | ||||
Unrealized loss on marketable securities
|
65,874 | 65,560 | ||||||
Total comprehensive loss
|
$ | 3,100,374 | $ | 2,236,972 | ||||
Net loss per share, basic and diluted
|
$ | (0.11 | ) | $ | (0.08 | ) | ||
Weighted average number of common shares outstanding, basic and diluted
|
28,119,521 | 27,661,499 |
Three months ended July 31,
|
||||||||
2015
|
2014
|
|||||||
(Unaudited)
|
(Unaudited)
|
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES
|
||||||||
Net Loss
|
$ | (3,034,500 | ) | $ | (2,171,412 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities
|
||||||||
Depreciation and amortization
|
12,650 | 38,486 | ||||||
Interest on debt instruments
|
- | 45,606 | ||||||
Issuance and vesting of compensatory stock options and warrants
|
43,997 | 71,032 | ||||||
Issuance of common stock as compensation
|
268 | 14,840 | ||||||
Change in the fair value of warrants
|
33,673 | (274,196 | ) | |||||
Amortization of premium on marketable securities
|
251,094 | 9,728 | ||||||
Changes in operating assets and liabilities
|
||||||||
Accounts receivable, prepaid expenses and other assets
|
94,175 | 204,949 | ||||||
Accounts payable and accrued liabilities
|
(1,244,332 | ) | 78,590 | |||||
Net cash used in operating activities
|
(3,842,975 | ) | (1,982,377 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES
|
||||||||
Purchase of marketable securities
|
(4,222,486 | ) | (35,627,219 | ) | ||||
Sale of marketable securities
|
3,858,298 | 1,065,360 | ||||||
Purchase of property and equipment
|
(16,688 | ) | - | |||||
Capitalization of patent costs and license rights
|
- | (15,095 | ) | |||||
Net cash used in investing activities
|
(380,876 | ) | (34,576,954 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES
|
||||||||
Proceeds from sale of common stock and exercise of stock options and warrants, net of related expenses and payments
|
- | 543,998 | ||||||
Payments on notes - short-term
|
(51,785 | ) | (347,561 | ) | ||||
Net cash (used in) provided by financing activities
|
(51,785 | ) | 196,437 | |||||
Net change in cash and cash equivalents
|
(4,275,636 | ) | (36,362,894 | ) | ||||
Cash and cash equivalents, beginning of period
|
7,926,491 | 58,320,555 | ||||||
Cash and cash equivalents, end of period
|
$ | 3,650,855 | $ | 21,957,661 | ||||
Cash paid for:
|
||||||||
Interest
|
$ | 1,103 | $ | 655 |
(1) | The Company issued 255 shares of restricted common stock for the payment of interest accrued on convertible notes. The shares were issued at a conversion price of $45.10 per share for the payment of $11,500 interest payable on convertible notes with a gross carrying value of $300,000. |
Three months ended July 31,
|
||||||||
2015
|
2014
|
|||||||
Options to purchase common stock
|
3,752,698 | 3,694,282 | ||||||
Warrants to purchase common stock
|
2,728,236 | 2,553,236 | ||||||
Restricted stock
|
367 | 12,384 |
July 31, 2015
|
||||||||||||||||||||
Amortized Cost
|
Accrued Interest
|
Gross Unrealized Gains
|
Gross Unrealized losses
|
Estimated Fair Value
|
||||||||||||||||
Obligations of U.S. Government and its agencies
|
$ | 1,199,051 | $ | 4,401 | $ | 375 | $ | - | $ | 1,203,827 | ||||||||||
Corporate debt securities
|
38,698,288 | 359,679 | - | (39,531 | ) | 39,018,436 | ||||||||||||||
Total investments
|
$ | 39,897,339 | $ | 364,080 | $ | 375 | $ | (39,531 | ) | $ | 40,222,263 |
July 31,
2015
|
April 30,
2015
|
|||||||
Maturing in one year or less
|
$ | 17,661,213 | $ | 9,200,082 | ||||
Maturing after one year through three years
|
22,561,050 | 30,974,961 | ||||||
Total investments
|
$ | 40,222,263 | $ | 40,175,043 |
Series C Warrants
|
July 31,
2015
|
April 30,
2015
|
||||||
Closing stock price
|
$ | 3.71 | $ | 3.42 | ||||
Expected dividend rate
|
0 | % | 0 | % | ||||
Expected stock price volatility
|
79.98 | % | 83.53 | % | ||||
Risk-free interest rate
|
1.26 | % | 1.23 | % | ||||
Expected life (years)
|
3.98 | 4.23 |
Fair Value Measurements at Reporting Date Using
|
||||||||||||||||
Balance as of
July 31,
2015
|
Quoted prices in Active Markets for Identical Securities (Level 1)
|
Significant Other Observable Inputs (Level 2)
|
Significant Unobservable Inputs (Level 3)
|
|||||||||||||
Current Assets
|
||||||||||||||||
Cash and cash equivalents
|
$ | 3,650,855 | $ | 3,650,855 | $ | - | $ | - | ||||||||
Marketable securities
|
$ | 17,661,213 | $ | - | $ | 17,661,213 | $ | - | ||||||||
Long-term Assets
|
||||||||||||||||
Marketable securities
|
$ | 22,561,050 | $ | - | $ | 22,561,050 | $ | - | ||||||||
Current Liabilities
|
||||||||||||||||
Warrant liabilities
|
$ | 606,118 | $ | - | $ | - | $ | 606,118 |
Fair Value Measurements at Reporting Date Using
|
||||||||||||||||
Balance as of
April 30,
2015
|
Quoted prices in Active Markets for Identical Securities (Level 1)
|
Significant Other Observable Inputs (Level 2)
|
Significant Unobservable Inputs (Level 3)
|
|||||||||||||
Current Assets
|
||||||||||||||||
Cash and cash equivalents
|
$ | 7,926,491 | $ | 7,926,491 | $ | - | $ | - | ||||||||
Marketable securities
|
$ | 9,200,082 | $ | - | $ | 9,200,082 | $ | - | ||||||||
Long-term Assets
|
||||||||||||||||
Marketable securities
|
$ | 30,974,961 | $ | - | $ | 30,974,961 | $ | - | ||||||||
Current Liabilities
|
||||||||||||||||
Warrant liabilities
|
$ | 572,445 | $ | - | $ | - | $ | 572,445 |
July 31,
2015
|
April 30,
2015
|
|||||||
R&D materials
|
$ | - | $ | 29,479 | ||||
Other
|
29,144 | 29,144 | ||||||
$ | 29,144 | $ | 58,623 |
July 31,
2015
|
April 30,
2015
|
|||||||
Laboratory equipment
|
$ | 514,214 | $ | 514,214 | ||||
Computer equipment and software
|
139,984 | 123,295 | ||||||
Office furniture and fixtures
|
130,192 | 130,192 | ||||||
784,390 | 767,701 | |||||||
Less: Accumulated depreciation
|
(730,029 | ) | (717,379 | ) | ||||
$ | 54,361 | $ | 50,322 |
July 31,
2015
|
April 30,
2015
|
|||||||
Operating costs
|
$ | 1,812,651 | $ | 2,053,597 | ||||
Employee related
|
106,929 | 596,137 | ||||||
Restructuring liability
|
- | 10,932 | ||||||
$ | 1,919,580 | $ | 2,660,666 |
Asset Category
|
Weighted Average Amortization Period (in Years)
|
Value Assigned
|
Accumulated Amortization
|
Impairments
|
Carrying Value (Net of Impairments and Accumulated Amortization)
|
|||||||||||||||
IPR&D
|
N/A | $ | 22,000,000 | $ | - | $ | - | $ | 22,000,000 | |||||||||||
Patents
|
10.3 | 806,771 | (327,476 | ) | (479,295 | ) | - | |||||||||||||
License Rights
|
13.6 | 630,666 | (181,484 | ) | (449,182 | ) | - | |||||||||||||
Trademarks
|
N/A | 106,386 | (106,386 | ) | - | |||||||||||||||
Total
|
$ | 23,543,823 | $ | (1,034,863 | ) | $ | 22,000,000 |
Shares Available for Grant
|
||||
Balances, at April 30, 2015
|
122,399 | |||
Options granted
|
(60,050 | ) | ||
Options cancelled/forfeited
|
650 | |||
Restricted stock granted
|
(430 | ) | ||
Restricted stock cancelled/forfeited
|
66 | |||
Balances, at July 31, 2015
|
62,635 |
Outstanding Options
|
||||||||
Number of Shares
|
Weighted Average Exercise Price
|
|||||||
Balances, at April 30, 2015
|
3,693,298 | $ | 5.70 | |||||
Options granted
|
60,050 | $ | 3.42 | |||||
Options cancelled
|
(650 | ) | $ | 35.09 | ||||
Balances, at July 31, 2015
|
3,752,698 | $ | 5.66 |
For the three ended July 31,
|
||||||||
2015
|
2014
|
|||||||
Risk-free interest rate (weighted average)
|
1.87 | % | 2.23 | % | ||||
Expected volatility (weighted average)
|
87.55 | % | 98.43 | % | ||||
Expected term (in years)
|
7 | 7 | ||||||
Expected dividend yield
|
0.00 | % | 0.00 | % |
Outstanding Restricted Stock Grants
|
||||||||
Number of Shares
|
Weighted Average Grant Date Fair Value
|
|||||||
Balances, at April 30, 2015
|
90 | $ | 4.01 | |||||
Restricted stock granted
|
430 | $ | 3.42 | |||||
Restricted stock vested
|
(87 | ) | $ | 3.61 | ||||
Restricted stock cancelled
|
(66 | ) | $ | 3.57 | ||||
Balances, at July 31, 2015
|
367 | $ | 3.49 |
●
|
Efficiently conduct clinical development to establish clinical proof of concept with our lead product candidates;
|
●
|
Efficiently explore new high-potential therapeutic applications, leveraging third-party research collaborations and our results from related areas;
|
●
|
Continue to expand our intellectual property portfolio; and
|
●
|
Enter into licensing or product co-development arrangements in certain areas, while out-licensing opportunities in non-core areas.
|
●
|
Cash and cash equivalents, including the fair-value of our marketable securities, were $43.9 million at July 31, 2015.
|
●
|
Our loss from operations was $3.1 million for the first quarter of fiscal 2016 compared to $2.2 million for the three months ended July 31, 2014.
|
●
|
Net cash used in operating activities was $3.8 million and $2.0 million for the three months ended July 31, 2015 and 2014, respectively.
|
●
|
Conducting well-designed studies early in the clinical development process to establish a robust foundation for subsequent development, partnership and expansion into complementary areas;
|
●
|
Working with collaborators and partners to accelerate product development, reduce our development costs, and broaden our commercialization capabilities;
|
●
|
Gaining regulatory approval for the continued development and commercialization of our products in the United States; and
|
●
|
Developing new intellectual property to enable us to file patent applications that cover new applications of our existing technologies and product candidates.
|
Three months ended July 31,
|
Increase/ (Decrease)
|
% Increase/ (Decrease)
|
||||||||||||||
2015
|
2014
|
|||||||||||||||
Legal and professional fees
|
$ | 474,173 | $ | 693,098 | $ | (218,925 | ) | (32 | ) % | |||||||
Personnel costs
|
637,025 | 562,202 | 74,823 | 13 | % | |||||||||||
Other costs
|
206,186 | 124,698 | 81,488 | 65 | % | |||||||||||
Facilities
|
41,904 | 39,966 | 1,938 | 5 | % | |||||||||||
Depreciation and amortization
|
9,316 | 29,895 | (20,579 | ) | (69 | ) % |
- |
Costs associated with investor relations and communication decreased approximately $214,000 in the current period. This decrease was due primarily to fees paid in the prior year to a third party investor relations firm that is no longer providing marketing and corporate communications services to us in the current period.
|
- |
Board of Directors fees decreased in the current period by approximately $34,000. This decrease was due primarily to a reduction in the recognized expense for the vesting of stock options awarded in the current period as compared to the recognized expense for stock options awarded in the same period of the prior year.
|
-
|
Consulting costs increased approximately $36,000 in the current period due primarily to fees paid to a third party consulting firm for ongoing development and testing of our internal control framework that were not incurred in the same period of the prior year.
|
Three months ended July 31,
|
Increase/ (Decrease)
|
% Increase/ (Decrease)
|
||||||||||||||
2015
|
2014
|
|||||||||||||||
Clinical and preclinical development
|
$ | 1,540,135 | $ | 778,015 | $ | 762,120 | 98 | % | ||||||||
Personnel costs
|
126,163 | 158,561 | (32,398 | ) | (20 | ) % | ||||||||||
Consulting
|
67,969 | 4,233 | 63,736 | 1506 | % | |||||||||||
Other costs
|
11,634 | 25,705 | (14,071 | ) | (55 | ) % |
Three months ended July 31,
|
Increase/ (Decrease)
|
% Increase/ (Decrease)
|
||||||||||||||
2015
|
2014
|
|||||||||||||||
Interest expense
|
$ | 1,103 | $ | 46,260 | $ | (45,157 | ) | (98 | ) % |
Three months ended July 31,
|
(Increase)/ Decrease
|
|||||||||||
2015
|
2014
|
|||||||||||
Other income, net
|
$ | (81,108 | ) | $ | (291,221 | ) | $ | 210,113 |
Three months ended July 31,
|
||||||||
2015
|
2014
|
|||||||
Net cash used in operating activities
|
$ | (3,842,975 | ) | $ | (1,982,377 | ) | ||
Net cash used in investing activities
|
(380,876 | ) | (34,576,954 | ) | ||||
Net cash (used in) provided by financing activities
|
(51,785 | ) | 196,437 |
●
|
the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;
|
●
|
the outcome, timing and cost of regulatory approvals and the regulatory approval process;
|
●
|
delays that may be caused by changing regulatory requirements;
|
●
|
the number of product candidates that we pursue;
|
●
|
the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;
|
●
|
the timing and terms of future in-licensing and out-licensing transactions;
|
●
|
the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;
|
●
|
the cost of procuring clinical and commercial supplies of our product candidates;
|
●
|
the extent to which we acquire or invest in businesses, products or technologies; and
|
●
|
the possible costs of litigation.
|
Payments Due by Period
|
||||||||||||||||||||
Less than
|
More than
|
|||||||||||||||||||
Total
|
1 Year
|
1-3 Years
|
3-5 Years
|
5 Years
|
||||||||||||||||
Operating Lease Obligations
|
$ | 66,442 | $ | 66,442 | $ | - | $ | - | $ | - |
Period
|
Total Number of Shares Purchased (1)
|
Average Price Paid per Share (2)
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
|
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
|
||||||||||||
May 1, 2015 - May 31, 2015
|
- | $ | - | - | $ | - | ||||||||||
June 1, 2015 - June 30, 2015
|
- | $ | - | - | $ | - | ||||||||||
July 1, 2015 - July 31, 2015
|
59 | $ | 3.68 | - | $ | - | ||||||||||
Total
|
59 | $ | 3.68 | - | $ | - |
(1)
|
Represents shares repurchased in connection with tax withholding obligations under the 1999 Amended Stock Plan.
|
(2)
|
Represents the average price paid per share for the shares repurchased in connection with tax withholding obligations under the 1999 Amended Stock Plan.
|
TENAX THERAPEUTICS, INC.
|
|||
Date: September 9, 2015
|
By:
|
/s/ Michael B. Jebsen | |
Michael B. Jebsen | |||
Chief Financial Officer | |||
(On behalf of the Registrant and as Principal Financial Officer)
|
No.
|
Description
|
|
3.1 |
Third Amended and Restated Bylaws.*
|
|
Description of Non-Employee Director Compensation.*
|
||
10.2
|
First Amendment to Employment Agreement with John Kelley dated June 18, 2015. (1)
|
|
10.3
|
First Amendment to Second Amended and Restated Employment Agreement with Michael B. Jebsen dated June 18, 2015. (1)
|
|
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
|
||
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
|
||
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
101.INS
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
(1)
|
These documents were filed as exhibits to the current report on Form 8-K filed by Tenax Therapeutics with the SEC on June 19, 2015 and are incorporated herein by this reference.
|
●
|
An annual director fee in each fiscal year of $45,000 ($55,000 for our board chairman), which is paid in equal quarterly installments on the first day of each fiscal quarter;
|
●
|
An annual audit committee member fee in each fiscal year of $7,500 ($15,000 for our audit committee chairman), which is paid in equal quarterly installments on the first day of each fiscal quarter;
|
●
|
An annual compensation committee member fee in each fiscal year of $5,000 ($10,000 for our compensation committee chairman), which is paid in equal quarterly installments on the first day of each fiscal quarter;
|
●
|
An annual nominating and corporate governance committee member fee in each fiscal year of $3,500 ($7,000 for our nominating and corporate governance committee chairman), which is paid in equal quarterly installments on the first day of each fiscal quarter;
|
●
|
An annual grant of 10,000 stock options (25,000 stock options in the initial year), which vest one-year after the grant date and are exercisable for a period of ten years, issued on the first day of each fiscal year; and
|
●
|
Reimbursement of travel and related expenses for attending Board and Committee meetings, as incurred.
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Tenax Therapeutics, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ John P. Kelley
|
|
|
John P. Kelley
|
||
Chief Executive Officer
|
||
(Principal Executive Officer) |
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Tenax Therapeutics, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Michael B. Jebsen
|
|
|
Michael B. Jebsen
|
||
Chief Financial Officer
|
||
(Principal Financial Officer) |
/s/ John P. Kelley
|
|
|
John P. Kelley
|
||
Chief Executive Officer
|
||
(Principal Executive Officer) |
/s/ Michael B. Jebsen
|
|
|
Michael B. Jebsen
|
||
Chief Financial Officer
|
||
(Principal Financial Officer) |